As an innovative genomics cancer diagnostics company, Agendia uses its knowledge and expertise in the application of clinically useful gene expression profiling to facilitate breast cancer diagnosis, breast cancer prognosis and breast cancer treatment. Leveraging the advancements generated by the Human Genome Project and a cutting edge genomics microarray platform, Agendia’s MammaPrint breast cancer test is designed to determine a patient’s risk of metastases, therefore providing a more personalized approach to breast cancer therapy.

With more and more women receiving an annual mammogram as part of their routine screening for breast cancer, physicians are identifying women with early stage breast cancer that have very small tumors. When a tumor is identified by mammography and diagnosed as invasive ductal carcinoma or invasive lobular carcinoma, a woman is faced with a variety of difficult decisions regarding which type of breast cancer treatment to choose; ranging from breast surgery options such as lumpectomy versus mastectomy to adjuvant treatment decisions such as hormone therapy alone or in combination with chemotherapy.

With MammaPrint, physicians and their patients have an FDA-cleared breast cancer test that can help deliver more personalized breast cancer treatment. MammaPrint provides physicians with an accurate assessment of their patients’ true risk of breast cancer recurrence, thereby helping determine the need for adjuvant chemotherapy, hormone therapy (e.g. Tamoxifen), and targeted biological therapy.